Break Up Big Medicine Act

The Break Up Big Medicine Act (S.3822) was introduced on February 10, 2026 by Senator Warren (D-MA) with Senator Hawley (R-MO) as the sole cosponsor and referred to the Senate Committee on the Judiciary. This is an early-stage authorization bill with no direct funding; it does not appropriate money but would mandate corporate restructuring through divestiture requirements. The bill's bipartisan sponsorship (Democrat + Republican) gives it more credibility than a partisan proposal, but the single-cosponsor count and early referral status indicate this is a statement bill unlikely to advance in the current Congress without significant additional support. The money trail here is negative: no new spending is authorized. Instead, the bill forces divestitures from existing market structures. Vertically integrated healthcare conglomerates that combine insurance, PBM, and care delivery under one roof would need to unwind those holdings. The primary mechanism is a legal prohibition — not a tax, subsidy, or procurement — meaning compliance costs would be borne entirely by affected companies through legal fees, restructuring charges, and lost synergies. For UNH, which operates the nation's largest PBM (Optum Rx) alongside the largest health insurer, the forced separation could be worth over $100 billion in enterprise value destruction. Real market data shows consistent downward pressure across the healthcare sector over the past 30 days. As of April 28, 2026: PFE declined 2.07% in the last month to $26.48 (near its 52-week low of $21.97); JNJ fell 5.27% to $227.79; MRK dropped 8.02% to $110.03; AMGN declined 2.64% to $339.57; GILD fell 3.72% to $129.26; and BIIB fell slightly 0.25% to $183.38. While this broad weakness likely reflects multiple factors (including the executive order on mental health therapies which creates a favorable regulatory environment for psychedelic-focused biotechs like $CMPS, $MNMD, and $ATAI), the Break Up Big Medicine Act adds legislative overhang for integrated companies without directly benefiting any specific pharma player. Legislative timeline: The bill faces a very long path. It was referred to the Judiciary Committee, which typically handles antitrust matters. No hearings have been scheduled. Even with bipartisan cosponsors, this is a major structural reform that would face fierce industry opposition from healthcare conglomerates, hospital systems, and pharmacy chains. Passage in the 119th Congress is unlikely unless the bill gains substantial committee momentum, which will be visible through additional cosponsors and committee markups in late 2026.